MitrAssist: Funding, Investors & Team (Sep 2026)
MitrAssist has introduced a new method for treating mitral regurgitation (MR) that is minimally invasive. Their mitral valve implant works with the natural valve without causing any damage to its functionality. Unlike current repair or replacement techniques, MitrAssist's approach involves placing their proprietary valve implant on top of the natural valve to improve its functionality. This innovative "valve-in-valve" approach addresses the challenges of MR and offers a better treatment solution for all MR patients. It is superior to both current and upcoming minimally invasive solutions.
MitrAssist has raised $100M across 1 funding round on record, the most recent a Series C of $100M announced in Sep 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
MitrAssist Company Profile and Key Stats
Latest funding round on record: Sep 2023.
MitrAssist Funding Rounds
MitrAssist Founders and Leadership Team
Contact details for the MitrAssist team: 1 of 1 has an email address on file.
Start 14-day free trial →MitrAssist Funding Compared to Other Biotechnology Startups
MitrAssist's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like MitrAssist in Biotechnology and Misgav Dov
Companies Similar to MitrAssist
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
MitrAssist Funding FAQs
What does MitrAssist do?
MitrAssist has introduced a new method for treating mitral regurgitation (MR) that is minimally invasive. Their mitral valve implant works with the natural valve without causing any damage to its functionality. Unlike current repair or replacement techniques, MitrAssist's approach involves placing their proprietary valve implant on top of the natural valve to improve its functionality. This innovative "valve-in-valve" approach addresses the challenges of MR and offers a better treatment solution for all MR patients. It is superior to both current and upcoming minimally invasive solutions.
How much funding has MitrAssist raised?
MitrAssist has raised $100M across 1 round on record. The most recent is a Series C of $100M announced in Sep 2023.
When did MitrAssist last raise funding?
MitrAssist's most recent funding round on record is a Series C of $100M, announced in Sep 2023.
Who is the CEO of MitrAssist?
Gil Naor is listed as CEO at MitrAssist.
Where is MitrAssist headquartered?
MitrAssist is based in Misgav Dov, Hamerkaz, Israel.
How many employees does MitrAssist have?
MitrAssist is in the 1-10 employee band.
How does MitrAssist's funding compare to other Biotechnology startups?
MitrAssist's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's MitrAssist Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MitrAssist is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.